

## METABOLOMICS: TECHNOLOGIES AND GLOBAL MARKETS



**BIO055B**  
November 2015

Robert Hunter  
*Project Analyst*

ISBN: 1-62296-180-3



**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	2
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	3
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL METABOLOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL METABOLOMIC MARKET BY APPLICATION, 2014-2020 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW OF METABOLOMICS	9
METABOLITES	9
METABOLOMICS	9
METABOLOMIC HISTORY	9
<i>TABLE 1 HUMAN METABOLOME PROJECT AND DATABASE, 2006-2013</i>	11
METABOLISM BASICS	11
CATABOLIC AND ANABOLIC PATHWAYS	12
<i>TABLE 2 CELLULAR RESPIRATION STAGES</i>	12
ADENOSINE TRIPHOSPHATE	12
ENZYME ROLE	13
<i>TABLE 3 FACTORS IMPACTING ENZYME ACTIVITY</i>	13
FEEDBACK INHIBITION	14
LOCATED IN MITOCHONDRIA	14
OXIDATION AND REDUCTION REACTIONS	14
DEHYDROGENASES	14
ELECTRON TRANSPORT CHAIN	14
OXIDATIVE AND SUBSTRATE-LEVEL PHOSPHORYLATION	15
GLYCOLYSIS	15
KREBS CYCLE	15
ACETYL COA	16
NADH AND FADH <sub>2</sub> DONATE ELECTRONS	16
ELECTRON TRANSPORTERS: FLAVOPROTEIN AND CYTOCHROMES	16
TRICARBOXYLIC ACID CYCLE	17
ADENOSINE TRIPHOSPHATE SYNTHESIS	17
FERMENTATION	17
FOOD TO ENERGY	18
LIPID PROCESSING	18
FATTY ACID BETA-OXIDATION IN THE HEART	19
KETOSIS	19

<b>TOPIC</b>	<b>PAGE NO.</b>
BENEFITS	19
METABOLOMES	20
LARGE BOWEL MICROFLORA	20
URINE METABOLOME	20
FOOD METABOLOME	20
LIPIDOMICS	21
FLUXOMICS	21
APPLICATIONS	22
CHALLENGES	23
ANALYTICAL TECHNOLOGIES	23
PERFORMANCE DRIVERS	23
LIMITS OF DETECTION	24
TARGETED VERSUS UNTARGETED APPROACHES	24
TARGETED ANALYSIS	24
METABOLITE PROFILING	24
METABOLIC FINGERPRINTING	25
UNTARGETED APPROACHES	25
MARKET SUB-SEGMENTS	25
<i>TABLE 4 PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)</i>	26
<i>FIGURE 1 PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)</i>	26
CHAPTER 4 METABOLOMIC ANALYTICAL PROCESSES AND INSTRUMENTS	28
METABOLOMIC PROCESS STEPS	28
<i>TABLE 5 TYPICAL ANALYTICAL METRABOLOMIC PROCESS STEPS</i>	28
METABOLOMIC ANALYSIS PROCEDURES	28
SAMPLE PREPARATION	28
EXTRACTION	29
DERIVATIZATION	29
SEPARATION AND DETECTION	30
DATA ANALYSIS	30
EQUIPMENT USED IN SAMPLE PREPARATION AND EXTRACTION	30
SEPARATION AND DETECTION PRODUCTS	31
SEPARATION	31
CHROMATOGRAPHY	31
High-Performance Liquid Chromatography	31
Gas Chromatography	31
CAPILLARY ELECTROPHORESIS	32
SEPARATION EQUIPMENT MARKET	32
SUPPLIERS	32
<i>TABLE 6 MAIN SEPARATION INSTRUMENT SUPPLIERS</i>	33
DETECTION	33
MASS SPECTROMETRY	33
<i>TABLE 7 MAIN MASS SPECTROSCOPY SUPPLIERS FOR LIFE SCIENCES</i>	33
Direct Injection	34
Mass Spectrometry Imaging	34
Mass Spectrometry Types	34

TOPIC	PAGE NO.
Ion Trap	34
Quadrupole	35
Time-of-Flight Mass Spectrometers	35
<i>TABLE 8 LEADING MASS SPECTROSCOPY SYSTEMS</i>	35
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY	36
NUCLEAR MAGNETIC RESONANCE VERSUS MASS SPECTROSCOPY	37
HYPHENATED APPROACHES	37
GAS CHROMATOGRAPHY-MASS SPECTROMETRY	37
SINGLE QUADRUPOLE INSTRUMENTS	38
TIME OF FLIGHT INSTRUMENTS	38
LIQUID CHROMATOGRAPHY MASS SPECTROSCOPY	38
CAPILLARY ELECTROPHORESIS-MASS SPECTROSCOPY	39
<i>TABLE 9 COMMON HYPHENATED PLATFORMS IN METABOLOMIC RESEARCH</i>	40
EMERGING DETECTION TECHNOLOGIES	40
MATRIX-ASSISTED LASER DESORPTION/IONIZATION	40
FOURIER TRANSFORM MASS SPECTROSCOPY	40
FOLDED FLIGHT PATH	41
COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY TIME-OF-FLIGHT MASS SPECTROSCOPY	41
MULTIPLE REACTION MONITORING	41
Targeted Untargeted Approach	41
Capillary Electrophoresis Mass Spectroscopy with Sheathless Interfaces	42
PROTEOMIC USE	42
Proteomics	42
METALLOMICS OVERVIEW	43
Tools Used in Metallomics	43
ANALYTICAL EQUIPMENT MARKET	43
<i>TABLE 10 GLOBAL MASS SPECTROMETRY MARKET, THROUGH 2017 (\$ BILLIONS)</i>	43
ANALYTICAL EQUIPMENT USED IN THE METABOLOMIC MARKET	44
<i>TABLE 11 GLOBAL ANALYTICAL EQUIPMENT USED IN THE METABOLOMIC MARKET, THROUGH 2020 (\$ MILLIONS)</i>	44
CHAPTER 5 ASSAY COMPONENTS AND KITS FOR METABOLOMICS	46
TARGETED METABOLOMICS	46
CHAPTER SCOPE	46
ASSAYS OVERVIEW	46
BACKGROUND ON ASSAYS AND ASSAY KITS	47
BIOCHEMICAL ASSAYS	47
CELL-BASED ASSAYS	47
CELL-BASED ASSAY TYPES	47
ASSAY READOUT: OVERVIEW OF DETECTION	48
CELL TYPES USED IN CELL-BASED ASSAYS	48
Immortalized Cell Lines and Primary Cells for Screening	48
Stem Cells at Scale	49
Cellular Dynamics Inc.	49
ASSAY COMMERCIAL CONSIDERATIONS	49
MICROPLATE PLATFORM	49

TOPIC	PAGE NO.
STANDARDS SETTING	50
CONTINUOUS INNOVATION	50
MICROPLATE READERS	51
ASSAY DETECTION OVERVIEW	51
FLUORESCENCE AS A DRIVER	52
HIGH-CONTENT SCREENING	52
Imaging Advances	53
Future Vision for High-Content Screening	54
<i>TABLE 12 HIGH-CONTENT SCREENING SUPPLIERS AND KEY ATTRIBUTES</i>	54
LABEL-FREE PLATFORMS	55
<i>TABLE 13 LABEL-FREE TECHNOLOGIES AND SUPPLIERS</i>	55
ELECTROPHYSIOLOGY	55
COMMERCIAL LANDSCAPE OF CELL-BASED ASSAYS	56
MAJOR ASSAYS TYPES USED IN METABOLOMICS RESEARCH	57
OTHER TYPES	57
<i>TABLE 14 OTHER ASSAY TYPES USED IN METABOLOMIC RESEARCH</i>	57
MAIN CELL METABOLISM ASSAY APPLICATIONS	57
<i>TABLE 15 MAIN CELL METABOLISM ASSAY APPLICATIONS</i>	58
ASSAYS USED IN METABOLISM	58
ADENOSINE TRIPHOSPHATE	59
ENZYSME ROLE	59
Phosphofructokinase	59
2-Phosphoglycerate	60
OXIDATION AND REDUCTION REACTIONS	60
DEHYDROGENASES	60
ELECTRON TRANSPORT CHAIN	60
OXIDATIVE AND SUBSTRATE-LEVEL PHOSPHORYLATION	60
GLYCOLYSIS	61
KREBS CYCLE	61
METABOLITE ASSAYS	61
ACETYL COA	62
NICOTINAMIDE ADENINE DINUCLEOTIDE AND NADH FADH <sub>2</sub>	62
Nicotinamide Adenine Dinucleotide Assays	63
OXIDATIVE STRESS ASSAYS	63
<i>TABLE 16 ASSAYS COMMONLY USED IN METABOLOMICS</i>	63
DRUG DISCOVERY USES	63
DRUG DISCOVERY DRIVERS	63
MITOCHONDRIA OPPORTUNITY	64
MITOCHONDRIAL FUNCTION AND CELL METABOLISM	64
MITOCHONDRIAL TOXICITY	65
<i>TABLE 17 MAJOR CATEGORIES OF ASSAYS USED IN METABOLOMICS FOR DRUG DISCOVERY</i>	65
TOOLS AND TECHNOLOGIES	66
TRADITIONAL METHODS	67
OTHER TECHNOLOGIES	67
NEW ANALYSIS TOOLS	67
BIOMARKER ASSAYS	67
FLUORESCENT DYES	67

<b>TOPIC</b>	<b>PAGE NO.</b>
BIOSENSING TECHNOLOGY	67
ADOPTION TRENDS	68
CANCER	68
OXYGEN CONSUMPTION ASSAY	68
SEAHORSE METABOLIC ANALYZERS	68
ASSAYS IN RELATED APPLICATIONS	69
<i>TABLE 18 OTHER ASSAYS COMMONLY USED ALONGSIDE METABOLOMIC ASSAYS</i>	69
CYTOTOXICITY: A MAJOR CATEGORY	70
CYTOTOXIC AND/OR CYTOSTATIC IMPACTS	70
SCREENING STRATEGIES	70
PERMEABILITY ASSAYS FOR CELL VIABILITY AND SURVIVAL	70
LACTATE DEHYDROGENASE ENZYME RELEASE ASSAYS	70
DYE UPTAKE	71
NEUTRAL RED UPTAKE FOR CELL SURVIVAL ASSAYS	71
ADVANTAGES AND DISADVANTAGES	71
METABOLIC ASSAYS FOR CELL VIABILITY AND SURVIVAL	71
MTT ASSAY	71
ADENOSINE TRIPHOSPHATE ASSAY	72
DISADVANTAGES OF METABOLIC ASSAYS	72
FLUOROMETRIC APPROACHES	72
ALTERED CELL ADHESION	72
ASSAYS FOR CELL DEATH	73
APOPTOSIS VERSUS NECROSIS	73
CASPASE ACTIVATION	73
MEMBRANE RESIDUES	73
CYTOCHROME C RELEASE FROM MITOCHONDRIA	73
ASSAYS FOR CYTOSTATIC OR LONG-TERM IMPACT	73
CLONOGENIC CELL SURVIVAL ASSAY	74
MULTIPLEX ASSAYS	74
COMPOSITE SCREENING STRATEGIES	75
HIGH THROUGHPUT	75
CORRELATION WITH GENE-EXPRESSION DATA	75
TOXICOLOGY AND ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION ASSAYS	76
ACUTE TOXICITY	76
CYTOTOXICITY ASSAY KIT	77
CHRONIC AND REPEATED DOSE TOXICITY	77
SUB-CHRONIC STUDIES	78
ACCUMULATION AND FREQUENCY OF EXPOSURE	78
DOSAGE LEVELS	78
DURATION	79
REVERSIBILITY	79
ANALYSIS	79
DEVELOPMENT OF REPEATED DOSE TOXICITY TESTING IN VITRO	79
CARCINOGENICITY AND GENOTOXICITY	80
IN VITRO METHODS: BACKGROUND AND RECENT DEVELOPMENTS	80
REGULATORY VERSUS DRUG DEVELOPMENT APPLICATIONS	81
AMES TEST	81

TOPIC	PAGE NO.
IN VITRO MICRONUCLEUS TEST	82
EFFORTS TO REDUCE FALSE POSITIVES	82
RECENT INNOVATIONS FOR SCREENING	82
METABOLITE ASSESSMENT	83
FUTURE CHALLENGE: NON-GENOTOXIC CARCINOGENS	84
REPRODUCTIVE AND DEVELOPMENTAL TOXICITY	84
FOLLOWING THE REPRODUCTIVE CYCLE	84
EMBRYOTOXICITY	85
MALE REPRODUCTIVE TOXICITY	85
FEMALE REPRODUCTIVE TOXICITY	85
DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY TESTING TYPES	86
ZEBRAFISH MODEL FOR DEVELOPMENTAL TOXICITY SCREENING	86
COMBINATIONS OF ZEBRAFISH AND STEM CELLS	87
BIOMEDICAL FRONTIERS: MALE TESTIS	87
ENDOCRINE DISRUPTOR SCREENING	88
ENVIRONMENTAL TOXICOLOGY IMPACTS IN VITRO METHODS	88
U.S. ENVIRONMENTAL PROTECTION AGENCY'S ENDOCRINE DISRUPTOR SCREENING PROGRAM	89
<i>TABLE 19 IN VITRO AND IN VIVO ASSAY TESTS IN THE TIER 1 SCREENING BATTERY, 2013</i>	89
HIGH-PRODUCTION VOLUME CHEMICALS	90
TOXCAST AND TOX 21 INITIATIVES	90
FUTURE CHALLENGE: THYROID DISRUPTION	90
BG1 ASSAY	90
LIVER TOXICITY APPLICATIONS	91
IMPORTANCE OF TWO-DIMENSIONAL VERSUS THREE-DIMENSIONAL SYSTEMS	92
IMMUNE MEDIATED DRUG-INDUCED LIVER INJURY	92
KIDNEY TOXICITY	93
FUTURE CHALLENGE: STEM CELL-DERIVED KIDNEY CELLS	94
ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION AND TOXICOKINETICS	94
IN VITRO DEVELOPMENTS	95
UNMET NEED FOR METABOLIC TRANSFORMATION	95
IN VITRO METABOLISM OFFERINGS	96
METABOLISM BY CYP450 ENZYMES: REACTION PHENOTYPING STUDIES	97
CYPROTEX	97
MICROFLUIDICS AND ORGANS-ON-A-CHIP	97
SUMMARY	98
COMMERCIAL CONSIDERATIONS	98
CELL-BASED ASSAY MARKET	98
GENOME SEQUENCING MARKET	99
MARKET	99
<i>TABLE 20 GLOBAL RESEARCH ASSAYS USED IN METABOLOMICS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	99
CHAPTER 6 BIOINFORMATICS IN METABOLOMICS	101
OVERVIEW	101
BIOINFORMATIC PROCESSES	101

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 21 BIOINFORMATIC PROCESSES FOR METABOLOMICS</i>	101
DATA COMPOSITION ANALYSIS AND PROCESSING	101
DATA COMPOSITION ANALYSIS	102
XCMS	102
Others	102
<i>TABLE 22 METABOLOMIC OPEN-ACCESS DATA-PROCESSING TOOLS</i>	102
DATA REDUCTION AND INTEGRATION	103
STATISTICAL APPROACHES AND CHALLENGES	103
GENOMICS INFLUENCE	104
METABOLOMIC METHODS	104
PRINCIPAL COMPONENT ANALYSIS	105
Upgrading Principal Component Analysis	105
FUNCTIONAL CLASSIFIERS BASED ON PATHWAYS AND NETWORKS	105
PATHWAY MAPS	105
KNOWLEDGE-BASED APPROACHES	106
DATA MODELING	107
RECONSTRUCTION	107
VERIFICATION	107
NETWORK SIMULATION	107
DATA VISUALIZATION	108
DATABASE CURATION AND MANAGEMENT	108
METABOLOMICS PUBLIC RESOURCES	108
<i>TABLE 23 METABOLOMIC PUBLIC RESOURCES</i>	109
SELECT DESCRIPTIONS	109
DAVID WISHART RESEARCH GROUP	109
METLIN	110
KYOTO ENCYCLOPEDIA OF GENES AND GENOMES	110
OTHERS	110
<i>TABLE 24 OTHER METABOLOMIC BIOINFORMATIC RESOURCES</i>	111
COMMERCIAL MARKET STRUCTURE	112
VENDORS AND EQUIPMENT MANUFACTURERS	112
BIOINFORMATICS COMPANIES AND SYSTEMS BIOLOGY PLAYERS WITH A SPECIFIC FOCUS ON METABOLOMICS RESEARCH	112
Thomson Reuters' Metadrug	112
GENEDATA SCREENER AND EXPRESSIONIST	113
QIAGEN	113
INGENUITY PATHWAY ANALYSIS	113
BMSYSTEMS	114
COMPANIES THAT DEVELOP THEIR OWN SOFTWARE	114
METABOLON	114
CHENOMX	115
LIMITATIONS	115
UNMET NEEDS	115
DATA STANDARDIZATION	116
MARKET	116
<i>TABLE 25 GLOBAL BIOINFORMATIC TOOLS USED IN THE METABOLOMIC MARKET, THROUGH 2020 (\$ MILLIONS)</i>	117



<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 7 CLINICAL BIOMARKERS	119
OVERVIEW	119
<i>TABLE 26 MAJOR CLINICAL METABOLOMIC APPLICATIONS</i>	119
BIOMARKER CHALLENGES	119
PROGRESS FROM PROTEOMICS	120
METABOLOMIC ADVANTAGE	121
APPLICATION ADOPTION	122
GENOMICS LEADERSHIP	123
METABOLOMICS' KEY ROLE	123
MAJOR CLINICAL APPLICATIONS	123
INBORN ERRORS OF METABOLISM	123
BACKGROUND	124
Amino Acid Disorders	124
Fatty Acid Oxidation Disorders	124
Organic Acid Disorders	124
ONSET AND SEVERITY	125
EXAMPLES OF INBORN ERRORS OF METABOLISM	125
INCIDENCE AND TESTING	125
PHARMACOGENOMICS	126
PHARMACOGENOMICS ADOPTION	126
CURRENT SUCCESSES IN PHARMACOGENOMICS	127
Warfarin	127
Simvastatin	128
Cancer Drugs	128
Cisplatin Chemotherapy	128
Anthracyclines	129
LIVER ENZYME CYP2C19	129
CLOPIDIGREL	129
CODEINE	130
HUMAN LEUKOCYTE ANTIGEN B	130
CARBAMAZEPINE	131
AZATHIOPRINE	131
MENTAL HEALTH	132
ANTIDEPRESSANTS	132
SEROTONIN	132
CATECHOL METHYL TRANSFERASE	133
PHARMACOKINETIC AND PHARMACODYNAMIC GENES	133
COMMERCIAL EXAMPLE	133
CHALLENGES AND FUTURE DIRECTIONS	133
VALIDATION	134
CANCER	135
CANCER HALLMARKS	135
CANCER METABOLISM OVERVIEW	136
CANCER GLUCOSE METABOLISM	137
CANCER GLUTAMINE METABOLISM	138
CANCER SERINE AND GLYCINE METABOLISM	138
ONE-CARBON METABOLISM	138

<b>TOPIC</b>	<b>PAGE NO.</b>
CANCER AND THE FOLATE CYCLE	139
Folic Acid	139
METHIONE CYCLE	140
CANCER AND GLUTATHIONE CYCLE	140
LIPID METABOLISM	140
CANCER DRUG APPLICATIONS	140
Folate Agonist Drugs	140
Nucleotide Metabolism	141
Targeting Metabolic Enzymes in Cancer	141
Enzyme Starvation	142
Mitochondrial Folate Metabolism	142
In Vitro Models	142
Path Forward	143
CARDIOVASCULAR AND METABOLIC DISEASE	143
APPLICATIONS	144
PLANNED MYOCARDIAL ISCHEMIA AND INFARCTION	144
EXERCISE STRESS TESTING	145
ALCOHOL SEPTAL ABLATION	145
NITRIC OXIDE METABOLIC PATHWAY	146
ANTHRACYCLINE-INDUCED CARDIOTOXICITY	146
ATRIAL FIBRILLATION	146
DETECTING HEART FAILURE VERSUS B-TYPE NATRIURETIC PEPTIDE	147
PULMONARY HYPERTENSION	147
Pulmonary Hypertension as Mitochondria Dysfunction	148
Pulmonary Hypertension and Insulin Resistance	148
ATHEROSCLEROSIS RISK	148
Lipid Profiles	149
Cholesterol	149
Particles	149
CHOLESTEROL TESTING CLINICAL USES AND MARKET	150
STATINS	150
POSSIBLE ADVERSE DRUG REACTIONS	151
SERUM MARKERS	151
STATIN DOSE MARKER	151
COADMINISTRATION	151
METABOLIZATION DIFFERENCES	151
GENETIC VARIABILITY	152
LIPID PROFILE	152
BEYOND STATINS TO MULTIMARKER APPROACH	153
Jupiter Trial	153
Jupiter Expands Statin Use	153
Jupiter Also Raises Diabetes Risk	153
Guidelines	154
SYSTEMIC AND VASCULAR INFLAMMATION	154
High-Sensitivity C-Reactive Protein	154
Myeloperoxidase	155
Lipoprotein-Associated Phospholipase-A2	155

<b>TOPIC</b>	<b>PAGE NO.</b>
ADVANCED LIPID TESTING	155
Apolipoprotein B and A1 (ApoA1)	155
Small-Dense LDL	156
Lipoprotein (a)	156
HDL2b	156
Particle Type	156
COMPANIES OFFERING ADVANCED LIPID TESTING	156
LIPOSCALE TEST	157
PRIMARY CARE PHYSICIANS	157
CLEVELAND HEARTLAB	157
NON-FASTING TRIGLYCERIDES	157
METABOLOMIC APPLICATIONS	157
LIPIDOMICS	158
CHOLINE METABOLISM	158
ACYLCARNITINES	158
Trimethylamine N-oxide	159
MICROFLORA-DERIVED CHOLINE METABOLITES	159
LINK WITH GUT MICROFLORA	160
DIABETES AND PRE-DIABETES	160
Insulin Resistance	160
Link with Obesity not Conclusive	161
TOOLS TO DETECT INSULIN RESISTANCE	161
COMPANIES OFFERING INSULIN-RESISTANCE TESTING	162
OTHER INSULIN-RESISTANCE TESTING	162
Branched-Chain Amino Acids: Insulin Resistance via Exercise Stress Testing	162
Branched-Chain Amino Acids and Gastric Bypass	163
LIVER DISEASES	164
METHYLATION DEFICIENCY	164
FOLATE DEFICIENCY	165
CLINICAL LIVER DISEASE	165
Diagnosis	166
Treatment	166
Research	167
Progress on Non-Alcoholic Fatty Liver Disease	167
OWL	168
European Association for the Study of the Liver	168
APPLICATIONS IN LIVER RESEARCH	168
Liver Metabolism Overview	168
Liver Function and Structure	169
Hepatocytes or Parenchymal Cells	169
Specialized Liver Endothelial Cells	170
Non-Parenchymal Stellate and Kupffer Cells	170
Morphogen Signaling	171
In Vitro Applications	171
Drug-Induced Liver Injury	172
Kiyatec	173
Liver Inflammation Models	173

<b>TOPIC</b>	<b>PAGE NO.</b>
Hepregen	173
Liver Regeneration	174
Achieving Hepatocyte Expansion Still Elusive	174
Cell Types	174
HepaRG	175
<i>TABLE 27 ORGANIZATIONS OFFERING IMMORTALIZED CELL LINES, 2013</i>	175
Human and Other Primary Hepatocytes	175
<i>TABLE 28 COMPANIES OFFERING PRIMARY CELLS, 2013</i>	176
Stem Cell-Derived Hepatocytes	176
RAFT for iPS Hepatocytes Longevity	176
Hepatotoxicity Screening Library	176
Stem Cell Companies	177
<i>TABLE 29 COMPANIES OFFERING STEM CELLS FOR LIVER SAFETY TESTING AND RESEARCH, 2013</i>	177
TOXICITY STUDIES AND NON-PARENCHYMAL CELLS AS DRIVERS OF IN VITRO DEVELOPMENT	177
TYPICAL END POINTS	178
KEY REQUIREMENTS	179
Cell-Cell Contacts Key for Differentiation and Functionality	179
Oxygen Supply	179
Co-Culture	179
Developments	180
Challenges	180
Benefits of Three-Dimensional Spheroids	180
High-Content Imaging and Analysis	180
Microfluidics	181
Dielectrophoretic Forces	181
HepaChip	182
Learnings from Microfluidics	183
Self-Organizing Systems	183
COMMERCIAL CONSIDERATIONS	184
LABORATORY-DEVELOPED TESTS	184
<i>TABLE 30 LABORATORY-DEVELOPED TEST PROVIDERS, 2015</i>	184
CLEVELAND HEARTLAB	185
MARKET	185
<i>TABLE 31 GLOBAL CLINICAL BIOMARKERS USED IN METABOLOMICS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	185
CHAPTER 8 COMPANY PROFILES	187
ABCAM	187
AGILENT TECHNOLOGIES INC.	188
ATHEROTECH DIAGNOSTICS LAB	189
BG MEDICINE INC.	189
BIOVISION INC.	190
CALITHERA BIOSCIENCES INC.	191
CHENOMX	192
CITOLAB	193
CLEVELAND HEARTLAB INC.	193

---

<b>TOPIC</b>	<b>PAGE NO.</b>
CLINMET INC.	194
COURTAGEN LIFE SCIENCES INC.	194
CYPROTEX PLC	194
EMD MILLIPORE	195
EXALENZ BIOSCIENCE LTD,	196
GENOMIND INC.	197
LECO CORP.	197
LUMINEX CORP.	198
METABOLOMIC DIAGNOSTICS	198
METABOLOMIC TECHNOLOGIES INC.	199
METABOLOMX	200
METABOLON INC.	200
METANOMICS GMBH	201
ONE WAY LIVER GENOMICS, S.L	202
PHENOMENOME DISCOVERIES INC.	203
PROMEGA CORP.	204
QIAGEN GMBH	205
SEAHORSE BIOSCIENCE	206
SIGMA-ALDRICH	207
STEMINA BIOMARKER DISCOVERY INC.	208
THERMO FISHER SCIENTIFIC	209
XENOTECH	209

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL METABOLOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	7
TABLE 1 HUMAN METABOLOME PROJECT AND DATABASE, 2006-2013	11
TABLE 2 CELLULAR RESPIRATION STAGES	12
TABLE 3 FACTORS IMPACTING ENZYME ACTIVITY	13
TABLE 4 PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)	26
TABLE 5 TYPICAL ANALYTICAL METRABOLOMIC PROCESS STEPS	28
TABLE 6 MAIN SEPARATION INSTRUMENT SUPPLIERS	33
TABLE 7 MAIN MASS SPECTROSCOPY SUPPLIERS FOR LIFE SCIENCES	33
TABLE 8 LEADING MASS SPECTROSCOPY SYSTEMS	35
TABLE 9 COMMON HYPHENATED PLATFORMS IN METABOLOMIC RESEARCH	40
TABLE 10 GLOBAL MASS SPECTROMETRY MARKET, THROUGH 2017 (\$ BILLIONS)	43
TABLE 11 GLOBAL ANALYTICAL EQUIPMENT USED IN THE METABOLOMIC MARKET, THROUGH 2020 (\$ MILLIONS)	44
TABLE 12 HIGH-CONTENT SCREENING SUPPLIERS AND KEY ATTRIBUTES	54
TABLE 13 LABEL-FREE TECHNOLOGIES AND SUPPLIERS	55
TABLE 14 OTHER ASSAY TYPES USED IN METABOLOMIC RESEARCH	57
TABLE 15 MAIN CELL METABOLISM ASSAY APPLICATIONS	58
TABLE 16 ASSAYS COMMONLY USED IN METABOLOMICS	63
TABLE 17 MAJOR CATEGORIES OF ASSAYS USED IN METABOLOMICS FOR DRUG DISCOVERY	65
TABLE 18 OTHER ASSAYS COMMONLY USED ALONGSIDE METABOLOMIC ASSAYS	69
TABLE 19 IN VITRO AND IN VIVO ASSAY TESTS IN THE TIER 1 SCREENING BATTERY, 2013	89
TABLE 20 GLOBAL RESEARCH ASSAYS USED IN METABOLOMICS MARKET, THROUGH 2020 (\$ MILLIONS)	99
TABLE 21 BIOINFORMATIC PROCESSES FOR METABOLOMICS	101
TABLE 22 METABOLOMIC OPEN-ACCESS DATA-PROCESSING TOOLS	102
TABLE 23 METABOLOMIC PUBLIC RESOURCES	109
TABLE 24 OTHER METABOLOMIC BIOINFORMATIC RESOURCES	111
TABLE 25 GLOBAL BIOINFORMATIC TOOLS USED IN THE METABOLOMIC MARKET, THROUGH 2020 (\$ MILLIONS)	117
TABLE 26 MAJOR CLINICAL METABOLOMIC APPLICATIONS	119
TABLE 27 ORGANIZATIONS OFFERING IMMORTALIZED CELL LINES, 2013	175
TABLE 28 COMPANIES OFFERING PRIMARY CELLS, 2013	176
TABLE 29 COMPANIES OFFERING STEM CELLS FOR LIVER SAFETY TESTING AND RESEARCH, 2013	177
TABLE 30 LABORATORY-DEVELOPED TEST PROVIDERS, 2015	184
TABLE 31 GLOBAL CLINICAL BIOMARKERS USED IN METABOLOMICS MARKET, THROUGH 2020 (\$ MILLIONS)	185

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL METABOLOMIC MARKET BY APPLICATION, 2014-2020 (\$ MILLIONS)	7
FIGURE 1 PUBLICATIONS USING KEYWORD METABOLOMICS IN THE SEARCH, 2002-2014 (TOTAL PER YEAR)	26